Publicaciones en colaboración con investigadores/as de Universitat de Barcelona (4)

2022

  1. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

2015

  1. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab

    Annals of Neurology, Vol. 77, Núm. 3, pp. 447-457

2014

  1. Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles

    Neurology: Neuroimmunology and NeuroInflammation, Vol. 1, Núm. 4

2012

  1. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis

    Multiple Sclerosis Journal, Vol. 18, Núm. 7, pp. 983-990